Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University College, London
Children's Oncology Group
Children's Oncology Group
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Children's Oncology Group
Merck Sharp & Dohme LLC
St. Jude Children's Research Hospital
Universität des Saarlandes
European Organisation for Research and Treatment of Cancer - EORTC
University of Sydney
Children's Oncology Group
EVIVE Biotechnology